FIXX - Homology Medicines, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
22.85
-0.95 (-3.99%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close23.80
Open23.66
Bid0.00 x 3100
Ask0.00 x 2200
Day's Range22.60 - 24.06
52 Week Range15.07 - 26.50
Volume103,734
Avg. Volume164,268
Market Cap852.536M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.50
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.50
Trade prices are not sourced from all markets
  • GlobeNewswire13 days ago

    Homology Medicines Achieves 2018 Goals and Prepares PKU Gene Therapy Program for the Clinic with Initial Data Expected in 2019

    Homology Medicines, Inc. (FIXX), a genetic medicines company, announced that it achieved all corporate goals for 2018, positioning the Company to start a Phase 1/2 clinical trial of the Company’s first gene therapy program in adults with phenylketonuria (PKU), with initial data expected in 2019. Homology closed out the year by nominating development candidates for two additional programs focused on pediatric rare genetic diseases, both of which have entered into IND-enabling studies.

  • GlobeNewswire13 days ago

    Homology Medicines Advances First Gene Editing Development Candidate into IND-Enabling Studies for Pediatric Patients with Phenylketonuria

    Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today that it has nominated an in vivo gene editing development candidate and initiated IND-enabling studies for the treatment of pediatric patients with phenylketonuria (PKU). Homology also completed its internal GMP manufacturing facility with capabilities to support both gene editing and gene therapy programs.

  • Is Homology Medicines, Inc. (FIXX) A Good Stock To Buy?
    Insider Monkeylast month

    Is Homology Medicines, Inc. (FIXX) A Good Stock To Buy?

    Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying for a while now that the current market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the fourth quarter, […]

  • Qatar Fund Building Venture Capital Unit for U.S. Startups
    Bloomberglast month

    Qatar Fund Building Venture Capital Unit for U.S. Startups

    The Qatar Investment Authority, created to handle the windfall from the country’s gas and oil exports, has invested in companies including Foursquare Labs Inc., biotech firm Rubius Therapeutics Inc., Homology Medicines Inc., Thoughtspot Inc. and Grail Inc., said the people, asking not to be identified because the deals are private.

  • Associated Press2 months ago

    Homology Medicines: 3Q Earnings Snapshot

    The Bedford, Massachusetts-based company said it had a loss of 40 cents per share. The gene editing company posted revenue of $954,100 in the period. Its adjusted revenue was $954,000. _____ This story ...

  • GlobeNewswire2 months ago

    Homology Medicines Reports Third Quarter 2018 Financial Results

    On Track to Begin and Report Initial Clinical Data from PKU Gene Therapy Trial and to Start IND-Enabling Studies in PKU Gene Editing and MLD Gene Therapy Programs Next Year.

  • GlobeNewswire2 months ago

    Homology Medicines to Present at Stifel Healthcare Conference

    BEDFORD, Mass., Nov. 08, 2018 -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will present during a fireside.

  • GlobeNewswire2 months ago

    Homology Medicines Presents Data on Platform’s Ability to Target the Central and Peripheral Nervous System and Therapeutic Potential in the Rare Disease Metachromatic Leukodystrophy

    Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today data demonstrating that Homology’s proprietary vectors are able to cross the blood-brain-barrier and have a positive impact on the rare neurological disorder metachromatic leukodystrophy (MLD). The presentation at the Society for Neuroscience (SfN) 2018 Annual Meeting reported biodistribution data on three of Homology’s 15 human-derived adeno-associated virus vectors (AAVHSCs).

  • PR Newswire4 months ago

    Homology Medicines to Present at Upcoming Conferences

    BEDFORD, Mass. , Oct. 1, 2018 /PRNewswire/ -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Homology will present at the following conferences: 2018 Cell & ...

  • PR Newswire5 months ago

    Homology Medicines to Participate in Gene Editing Panel at Citi's Biotech Conference

    BEDFORD, Mass. , Aug. 30, 2018 /PRNewswire/ -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will participate in a panel on gene editing ...

  • Homology Medicines Sees Hammer Chart Pattern: Time to Buy?
    Zacks5 months ago

    Homology Medicines Sees Hammer Chart Pattern: Time to Buy?

    Homology Medicines has been struggling lately, but the selling pressure may be coming to an end soon.

  • PR Newswire5 months ago

    Homology Medicines Reports Second Quarter 2018 Financial Results

    - Company on Track to Begin and Report Initial Data from Phase 1/2 Gene Therapy Program and Advance Gene Editing Platform into IND-Enabling Studies in PKU in 2019 - BEDFORD, Mass. , Aug. 13, 2018 /PRNewswire/ ...

  • PR Newswire6 months ago

    Homology Medicines Announces Peer-Reviewed Publication Demonstrating Efficient and Precise In Vivo Gene Editing Capabilities of Nuclease-Free Technology Platform

    BEDFORD, Mass. , July 16, 2018 /PRNewswire/ -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today a peer-reviewed publication demonstrating that Homology's technology ...

  • PR Newswire7 months ago

    Homology Medicines to Present at the National PKU Alliance Conference

    BEDFORD, Mass., July 5, 2018 /PRNewswire/ -- Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today that it will present data from its phenylketonuria (PKU) gene therapy program and will participate on a panel on emerging therapies at the National PKU Alliance (NPKUA) Conference July 5-8, 2018 at the Hilton Downtown Atlanta. "We look forward to the NPKUA Conference and contributing to the increased awareness of PKU and treatments that are being developed to help meet the high unmet medical need for this rare disease," stated Albert Seymour, Ph.D., Chief Scientific Officer of Homology.

  • PR Newswire7 months ago

    Homology Medicines Added to the Russell 3000® and Russell 2000® Indexes

    - Company Will Also Ring the Nasdaq Stock Market Opening Bell Today - BEDFORD, Mass. , June 25, 2018 /PRNewswire / -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today ...

  • PR Newswire8 months ago

    Homology Medicines Presents Data from PKU Gene Therapy Program Demonstrating Long-Term Durability of Treatment in IND-Enabling Studies

    BEDFORD, Mass., May 18, 2018 /PRNewswire/ -- Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today the presentation of data from its gene therapy and gene editing programs at the 21st Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT). New data presented from Homology's HMI-102 program, a gene therapy for phenylketonuria (PKU) in IND-enabling studies, demonstrate its potential as a one-time treatment designed to restore the normal metabolic pathway in PKU.

  • PR Newswire8 months ago

    Homology Medicines Reports First Quarter 2018 Financial Results

    - Company Completes IPO, Expands Board of Directors and Progresses IND-Enabling Studies to Support a PKU Clinical Gene Therapy Program with Initial Data Expected in 2019 - BEDFORD, Mass. , May 14, 2018 ...

  • PR Newswire8 months ago

    Homology Medicines to Present at Bank of America Merrill Lynch Healthcare Conference

    BEDFORD, Mass. , May 10, 2018 /PRNewswire/ -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will present at the Bank of America Merrill Lynch ...

  • PR Newswire9 months ago

    Homology Medicines Announces Upcoming Presentations on its Genetic Medicines Platform at the American Society of Gene & Cell Therapy Meeting

    BEDFORD, Mass., April 30, 2018 /PRNewswire/ -- Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today that data from its gene editing and gene therapy platform, including data from its phenylketonuria (PKU) programs, will be presented during the 21st Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) at the Hilton Chicago from May 16-19, 2018. Homology will present new data with HMI-102, the Company's gene therapy product candidate in IND-enabling studies for the treatment of PKU.

  • PR Newswire9 months ago

    Homology Medicines to Participate in the World Orphan Drug Congress

    BEDFORD, Mass., April 23, 2018 /PRNewswire/ -- Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today that Company management is scheduled to participate in the World Orphan Drug Congress USA 2018 at the Gaylord National Harbor Hotel in Oxon Hill, Maryland. The World Orphan Drug Congress is a global gathering of leaders in orphan drugs and includes presentations covering all aspects of orphan drug development and rare disease research.

  • Should You Be Concerned About Homology Medicines Inc’s (NASDAQ:FIXX) Shareholders?
    Simply Wall St.10 months ago

    Should You Be Concerned About Homology Medicines Inc’s (NASDAQ:FIXX) Shareholders?

    I am going to take a deep dive into Homology Medicines Inc’s (NASDAQ:FIXX) most recent ownership structure, not a frequent subject of discussion among individual investors. A company’s ownership structureRead More...

  • PR Newswire10 months ago

    Homology Medicines Announces Closing of Initial Public Offering

    BEDFORD, Mass., April 3, 2018 /PRNewswire/ -- Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today the closing of its initial public offering of 10,350,000 shares of common stock at a public offering price of $16.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,350,000 additional shares. The gross proceeds to Homology, before underwriting discounts and commissions, are $165,600,000. All of the shares of common stock in the offering were sold by Homology.

  • PR Newswire10 months ago

    Homology Medicines Announces Pricing of Initial Public Offering

    BEDFORD, Mass., March 27, 2018 /PRNewswire/ -- Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today the pricing of its initial public offering of 9,000,000 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Homology. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock from the Company at the initial public offering price, less the underwriting discounts and commissions.